evoke study semaglutide A Critical Appraisal of the and Evoke+ trials for Alzheimer's disease AD/PD 2026: Novo Nordisk's semaglutide

Keep reading to learn more about the supplements that support skin health

GLP-1 receptor agonists are increasingly recognized for their ability to aid in weight reduction by regulating appetite and food intake

What are the warning signs of pancreatitis whilst taking GLP-1 medication

The most common adverse reactions associated with tirzepatide to date have been GI, including nausea and vomiting, occurring at a frequency similar to that observed with semaglutide

Interpretation The benefit of GLP-1 RAs exceeded the harms for weight loss in the first 2 years of treatment, yet the net benefit was dependent on individual treatment goals (10% or 5% weight loss) and willingness to accept harms in pursuit of weight loss